Interferon-β for Treatment of COVID-19: Subcutaneous Administration more Effective

Results from the phase2 trial support the view that subcutaneous administration of IFN- β for treatment of COVID-19 enhances speed of recovery and reduces mortality.

The extraordinary situation presented by the COVID-19 pandemic has warranted exploring different possible avenues for the treatment of severe COVID-19 cases. Several new drugs are being tried and existing drugs being repurposed. Corticosteroids have already been found to be useful. Interferon therapy is already in use for viral infections like hepatitis. Can IFN be used against SARS CoV-2 in COVID-19?  

In preclinical trials earlier, IFN had proved to be effective against SARS CoV and MERS viruses. In July 2020, administration of Interferon-β through nebulisation (viz. pulmonary inhalation) route was reported to show promising results in treating severe COVID-19 cases based on data from phase 2 clinical trial 1,2.  

Now, the latest report based on data from phase 2 clinical trial conducted on 112 patients with COVID-19 hospitalized at Pitié-Salpêtrière in Paris, France suggests that administration of IFN- β through subcutaneous route enhances recovery rate and decreases mortality in COVID-19 cases 3.   

Interferons (IFN) are proteins secreted by the host cells in response to viral infections to signal the other cells for the presence of virus. The exaggerated inflammatory response in some of the COVID-19 patients is found to be associated with impaired IFN-1 response and blockade IFN-β secretion. It is used in China to treat viral pneumonia due to SARS CoV however its use is not standardised 4.  

The phase 3 clinical trial for use of Interferons (IFN) in treatment of severe COVID-19 patients is currently in progress. Approval will depend on whether the final results are within the acceptable range stipulated by the regulators.   

***

Sources:   

  1. NHS 2020. News- Inhaled drug prevents COVID-19 patients getting worse in Southampton trial. Posted on 20 July 2020. Available online at https://www.uhs.nhs.uk/ClinicalResearchinSouthampton/Research/News-and-updates/Articles/Inhaled-drug-prevents-COVID-19-patients-getting-worse-in-Southampton-trial.aspx Accessed on 12 February 2021.  
  1. Monk PD., Marsden RJ., Tear VJ., et al., 2020. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine, Available online 12 November 2020. DOI: https://doi.org/10.1016/S2213-2600(20)30511-7 
  1. Dorgham K., Neumann AU., et al 2021. Considering personalized Interferon-β therapy for COVID-19. Antimicrobial Agents Chemotherapy. Posted Online 8 February 2021. DOI: https://doi.org/10.1128/AAC.00065-21  
  1. Mary A., Hénaut L., Macq PY., et al 2020. Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b–Literature Review and Personal Preliminary Experience. Frontiers in Pharmacology., 30 November 2020. DOI:https://doi.org/10.3389/fphar.2020.592543.  

***

Latest

UK’s First Birth Following Living-donor Uterine Transplantation

The woman who had undergone the first living-donor uterus...

Qfitlia (Fitusiran): A Novel siRNA-based Treatment for Haemophilia  

Qfitlia (Fitusiran), a novel siRNA-based treatment for haemophilia has...

JWST’s Deep Field Observations Contravene Cosmological Principle

James Webb Space Telescope’s deep field observations under JWST...

Long-chain Hydrocarbons Detected on Mars  

An analysis of existing rock sample inside Sample Analysis at...

Newsletter

Don't miss

CoViNet: A New Network of Global Laboratories for Coronaviruses 

A new global network of laboratories for coronaviruses, CoViNet,...

COVID-19: Severe lung infection affects heart through “cardiac macrophage shift” 

It is known that COVID-19 increases the risk of...

JN.1 sub-variant: The Additional Public Health Risk Is Low at the Global Level

JN.1 sub-variant whose earliest documented sample was reported on 25...

COVID-19: JN.1 sub-variant has higher transmissibility and immune escape ability 

Spike mutation (S: L455S) is hallmark mutation of JN.1...

COVID-19 Not Over Yet: What We Know of the Latest Surge in China 

It is perplexing why China chose to lift zero-COVID...
SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

‘Bradykinin Hypothesis’ Explains the Exaggerated Inflammatory Response in COVID-19

A novel mechanism to explain the different unrelated symptoms of COVID-19 has come to light by exploiting the second fastest Supercomputer in the world...

COVID-19 Containment Plan: Social Distancing vs. Social Containment

The containment scheme based on 'quarantine' or 'social distancing' has emerged as the main tool in fight against COVID-19. But, there are concerns about...

COVID-19 Situation across Europe is Very Serious

COVID-19 situation across Europe and central Asia is very serious. According to WHO, Europe could face over 2 million COVID-19 deaths by March 2022. Wearing...